Anti-Inflammatory Effect of Dehydroxymethylepoxyquinomicin, a Nuclear factor–κB Inhibitor, on Endotoxin-Induced Uveitis in Rats In vivo and In vitro

REFERENCES

• de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30:452–470. doi:10.1016/j.preteyeres.2011.06.005.
   PubMed Web of Science ®Google Scholar
• Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother. 2010;11:1135–1146. doi:10.1517/14656561003713534.
   PubMed Web of Science ®Google Scholar
• Dunne JA, Jacobs N, Morrison A, Gilbert DJ. Efficacy in anterior uveitis of two known steroids and topical tolmetin. Br J Ophthalmol. 1985;69:120–125.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980;286:611–613.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Raymond W. Monocyte chemotactic activity induced by intravitreal endotoxin. Invest Ophthalmol Vis Sci. 1985;26:1267–1273.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Boney RS. Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis. Arch Ophthalmol. 1992;110:547–549.
   PubMedGoogle Scholar
• Bhattacherjee P, Williams RN, Eakins KE. An evaluation of ocular inflammation following the injection of bacterial endotoxin into the rat foot pad. Invest Ophthalmol Vis Sci. 1983;24:196–202.
   PubMed Web of Science ®Google Scholar
• Okumura A, Mochizuki M. Endotoxin-induced uveitis in rats: morphological and biochemical study. Jpn J Ophthalmol. 1988;32:457–465.
   PubMed Web of Science ®Google Scholar
• McMenamin PG, Crewe J. Endotoxin-induced uveitis. Kinetics and phenotype of the inflammatory cell infiltrate and the response of the resident tissue macrophages and dendritic cells in the iris and ciliary body. Invest Ophthalmol Vis Sci. 1995;36:1949–1959.
   PubMed Web of Science ®Google Scholar
• Shen DF, Chang MA, Matteson DM, Buggage R, Kozhich AT, Chan CC. Biphasic ocular inflammatory response to endotoxin-induced uveitis in the mouse. Arch Ophthalmol. 2000;118:521–527.
   PubMedGoogle Scholar
• Planck SR, Huang XN, Robertson JE, Rosenbaum JT. Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci. 1994;35:924–930.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Yoshimura N, Hangai M, Tanihara H, Honda Y. Interleukin-1 alpha, interleukin-1 beta, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1994;35:1107–1113.
   PubMed Web of Science ®Google Scholar
• Lennikov A, Kitaichi N, Noda K, et al. Amelioration of endotoxin-induced uveitis treated with an IkappaB kinase beta inhibitor in rats. Mol Vis. 2012;18:2586–2597.
   PubMed Web of Science ®Google Scholar
• de Vos AF, van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci. 1994;35:1100–1106.
   PubMed Web of Science ®Google Scholar
• Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15:362–374. doi:10.1038/nri3834.
   PubMed Web of Science ®Google Scholar
• Hayden MS, Ghosh S. NF-kappaB in immunobiology. Cell Res. 2011;21:223–244. doi:10.1038/cr.2011.13.
   PubMed Web of Science ®Google Scholar
• Wu J, Ding J, Yang J, Guo X, Zheng Y. MicroRNA roles in the nuclear factor Kappa B signaling pathway in Cancer. Front Immunol. 2018;9:546. doi:10.3389/fimmu.2018.00546.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Cujec TP, Yamanaka H, Kamatani N. Molecular aspects of rheumatoid arthritis: role of transcription factors. Febs J. 2008;275:4463–4470. doi:10.1111/j.1742-4658.2008.06582.x.
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Ariga S, To-E H, et al. Synthesis of NF-B activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett. 2000;10:865–869.
   PubMed Web of Science ®Google Scholar
• Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem. 2002;277:24625–24630. doi:10.1074/jbc.M112063200.
   PubMed Web of Science ®Google Scholar
• Umezawa K, Chaicharoenpong C. Molecular design and biological activities of NF-kappaB inhibitors. Mol Cells. 2002;14:163–167.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K. Inactivation of nuclear factor kappa B components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem. 2008;51:5780–5788. doi:10.1021/jm8006245.
   PubMed Web of Science ®Google Scholar
• Kosaka T, Miyajima A, Kikuchi E, et al. The novel NF-kappaB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats. Nephron Exp Nephrol. 2008;110:e17–24. doi:10.1159/000150314.
   PubMedGoogle Scholar
• Nishimura D, Ishikawa H, Matsumoto K, et al. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int J Oncol. 2006;29:713–719.
   PubMed Web of Science ®Google Scholar
• Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther. 2005;7:R1348–1359. doi:10.1186/ar1834.
   PubMed Web of Science ®Google Scholar
• Iwata D, Kitaichi N, Miyazaki A, et al. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice. Invest Ophthalmol Vis Sci. 2010;51:2077–2084. doi:10.1167/iovs.09-4030.
   PubMed Web of Science ®Google Scholar
• Jo YJ, Sonoda KH, Oshima Y, et al. Establishment of a new animal model of focal subretinal fibrosis that resembles disciform lesion in advanced age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:6089–6095. doi:10.1167/iovs.10-5189.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Keino H, Sato Y, Kudo A, Kawakami H, Okada AA. High mobility group box protein-1 in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2009;50:2283–2290. doi:10.1167/iovs.08-2709.
   PubMed Web of Science ®Google Scholar
• Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005;115:2363–2372. doi:10.1172/JCI23874.
   PubMed Web of Science ®Google Scholar
• Ohta K, Nakayama K, Kurokawa T, Kikuchi T, Yoshimura N. Inhibitory effects of pyrrolidine dithiocarbamate on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci. 2002;43:744–750.
   PubMed Web of Science ®Google Scholar
• Chang YH, Horng CT, Chen YH, et al. Inhibitory effects of glucosamine on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci. 2008;49:5441–5449. doi:10.1167/iovs.08-1784.
   PubMed Web of Science ®Google Scholar
• Kamoshita M, Ozawa Y, Kubota S, et al. AMPK-NF-kappaB axis in the photoreceptor disorder during retinal inflammation. PLoS One. 2014;9:e103013. doi:10.1371/journal.pone.0103013.
   PubMed Web of Science ®Google Scholar
• Kuraya D, Watanabe M, Koshizuka Y, et al. Efficacy of DHMEQ, a NF-kappaB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage. Transplantation. 2013;96:445–453. doi:10.1097/TP.0b013e31829b0744.
   PubMed Web of Science ®Google Scholar
• Inokawa S, Watanabe T, Keino H, et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1beta in human corneal fibroblasts. Graefes Arch Clin Exp Ophthalmol. 2015;253:557–563. doi:10.1007/s00417-014-2879-9.
   PubMed Web of Science ®Google Scholar
• de Vos AF, Klaren VN, Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci. 1994;35:3873–3883.
   PubMed Web of Science ®Google Scholar
• Leung KW, Barnstable CJ, Tombran-Tink J. Bacterial endotoxin activates retinal pigment epithelial cells and induces their degeneration through IL-6 and IL-8 autocrine signaling. Mol Immunol. 2009;46:1374–1386. doi:10.1016/j.molimm.2008.12.001.
   PubMed Web of Science ®Google Scholar
• Chui JJ, Li MW, Di Girolamo N, Chang JH, McCluskey PJ, Wakefield D. Iris pigment epithelial cells express a functional lipopolysaccharide receptor complex. Invest Ophthalmol Vis Sci. 2010;51:2558–2567. doi:10.1167/iovs.09-3923.
   PubMed Web of Science ®Google Scholar
• Shen DF, Buggage RR, Eng HC, Chan CC. Cytokine gene expression in different strains of mice with endotoxin-induced uveitis (EIU). Ocul Immunol Inflamm. 2000;8:221–225.
   PubMed Web of Science ®Google Scholar
• Gaudio PA. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm. 2004;12:169–192. doi:10.1080/092739490500192.
   PubMed Web of Science ®Google Scholar
• Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond). 2006;20:407–416. doi:10.1038/sj.eye.6701895.
   PubMed Web of Science ®Google Scholar
• Starenki DV, Namba H, Saenko VA, et al. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res. 2004;10:6821–6829. doi:10.1158/1078-0432.CCR-04-0463.
   PubMed Web of Science ®Google Scholar
• Ueki S, Yamashita K, Aoyagi T, et al. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Transplantation. 2006;82:1720–1727. doi:10.1097/01.tp.0000250548.13063.44.
   PubMed Web of Science ®Google Scholar
• Chiba T, Kondo Y, Shinozaki S, et al. A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. J Atheroscler Thromb. 2006;13:308–313.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Konno S, Ozaki M, et al. Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma. Clin Exp Allergy. 2012;42:1273–1281. doi:10.1111/j.1365-2222.2012.04007.x.
   PubMed Web of Science ®Google Scholar
• Ukaji T, Umezawa K. Novel approaches to target NF-κB and other signaling pathways in cancer stem cells. Adv Biol Regul. 2014;56:108–115. doi:10.1016/j.jbior.2014.06.001.
   PubMedGoogle Scholar
• de Castro Barbosa ML, Da Conceicao RA, Fraga AGM, et al. NF-κB signaling pathway inhibitors as anticancer drug candidates. Anticancer Agents Med Chem. 2017;17:483–490. doi:10.2174/1871520616666160729112854.
   PubMed Web of Science ®Google Scholar
• Miyake A, Dewan MZ, Ishida T, et al. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect. 2008;10:748–756. doi:10.1016/j.micinf.2008.04.002.
   PubMed Web of Science ®Google Scholar
• Fukushima T, Kawaguchi M, Yorita K, et al. Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma. Neuro Oncol. 2012;14:19–28. doi:10.1093/neuonc/nor168.
   PubMed Web of Science ®Google Scholar